Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. (Q44728848)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. |
scientific article |
Statements
1 reference
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. (English)
1 reference
Melby T
1 reference
Sista P
1 reference
DeMasi R
1 reference
Kirkland T
1 reference
Roberts N
1 reference
Salgo M
1 reference
Heilek-Snyder G
1 reference
Cammack N
1 reference
Matthews TJ
1 reference
Greenberg ML
1 reference
1 May 2006
1 reference
1 reference
22
1 reference
5
1 reference
375-385
1 reference
Identifiers
1 reference
1 reference